Novartis AG Form 6-K Summary: Fourth Quarter and Full Year 2006 Results
Business Context and Reporting Period
This Form 6-K, filed on January 24, 2007, reports the audited full-year and unaudited fourth-quarter financial results for Novartis AG for the period ended December 31, 2006. The filing incorporates a press release detailing record full-year performance driven by a strategic healthcare portfolio, including the integration of Chiron Corporation (acquired in April 2006) and the planned divestiture of the Medical Nutrition business to Nestlé.
Key Financial Metrics
| Metric | Full Year 2006 | Full Year 2005 | Q4 2006 | Q4 2005 |
|---|---|---|---|---|
| Net Sales (USD) | $37.02 billion | $32.21 billion | $10.05 billion | $8.66 billion |
| Operating Income (USD) | $8.17 billion | $6.91 billion | $1.82 billion | $1.49 billion |
| Net Income (USD) | $7.20 billion | $6.14 billion | $1.66 billion | $1.35 billion |
| Basic EPS (USD) | $3.06 | $2.63 | $0.70 | $0.58 |
| Operating Margin | 22.1% | 21.4% | 18.1% | 17.2% |
| Free Cash Flow (USD) | $4.34 billion | $4.67 billion | $1.68 billion | $1.61 billion |
| Net Liquidity (USD) | $0.65 billion | $2.48 billion | N/A | N/A |
| Debt/Equity Ratio | 0.18:1 | 0.25:1 | N/A | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Full-year net sales increased 15% (14% in local currencies), driven by volume growth (+6 percentage points) and acquisitions (+7 percentage points). The Pharmaceuticals division grew 11%, Sandoz grew 27%, and the new Vaccines and Diagnostics division contributed $956 million.
- Profitability: Operating income rose 18% to $8.17 billion. Excluding Chiron acquisition-related charges of $642 million, operating income would have increased 28%. Net income rose 17% to $7.2 billion (25% excluding Chiron charges).
- Divisional Performance:
- Pharmaceuticals: Diovan sales exceeded $4 billion (+15% lc) and Gleevec/Glivec topped $2.5 billion (+17% lc).
- Sandoz: Operating income more than doubled (+115%) due to new product launches and acquisitions (Hexal, Eon Labs).
- Consumer Health: Continuing operations grew 8%, though Q4 operating income declined 17% due to a contact lens recall in CIBA Vision.
- Liquidity: Net liquidity decreased from $2.5 billion to $0.7 billion, primarily due to the $5.7 billion cash outflow for the Chiron acquisition and other investments.
Guidance, Outlook, and Risks
- 2007 Outlook: Management expects another year of record net sales and earnings. Group net sales are projected to rise at a mid- to high-single-digit rate in local currencies. The Pharmaceuticals division is expected to grow at a mid-single-digit rate.
- Product Pipeline: Key launches anticipated for 2007-2008 include Exforge (hypertension), Tekturna/Rasilez (hypertension), Galvus (diabetes), and Lucentis (blindness). Regulatory approvals for Exforge were received in Europe in January 2007.
- Dividend: The Board proposed a dividend of CHF 1.35 per share for 2006, a 17% increase from 2005, representing the tenth consecutive year of a higher payout.
- Risks and Contingencies:
- Legal Proceedings: Ongoing antitrust litigation regarding Canadian drug importation and price-fixing allegations; outcomes remain uncertain.
- Regulatory: Delays in FDA approvals for Galvus and Tekturna/Rasilez due to additional data reviews.
- Divestiture: Completion of the Medical Nutrition sale to Nestlé is expected in the second half of 2007, subject to regulatory approval.
Investor Verification Checklist
- Verify the final purchase price allocation for the Chiron acquisition, specifically regarding goodwill and intangible assets, which remain provisional pending negotiations with Bayer-Schering AG.
- Monitor the regulatory status of Galvus (vildagliptin) and Tekturna/Rasilez (aliskiren) following FDA review extensions.
- Confirm the timeline and final terms of the Medical Nutrition divestiture to Nestlé.
- Assess the impact of the CIBA Vision product recall on future Consumer Health margins.
- Review the status of the Canadian Importation antitrust cases and potential for Supreme Court appeals.